Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma

detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Completed

Looking for future studies?

Key information

Conditions

Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Maisa Hashem Mohammed

Sohag, 82524, Egypt

About this study

renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitating accumulations of multiple mutations and augment resistance to immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in many human neoplasms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients suffer from renal cell carcinomas

Exclusion criteria

patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.

Treatment and study plan

sectioning and staining of renal neoplasms after nephrectomy operation

Diagnostic Test

nephrectomy operations will be done to patients diagnosed as having renel tumors

Primary outcomes

expression of survivin in neoplastic and adjacent normal renal tissues

Time frame: april, 2021

Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures..

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

A Retrospective Study

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: May 5, 2021
Registry last updated: May 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed